NVIDIA launches Jetson Thor robotics computers for physical AI systems
Nasus Pharma Ltd. (NSRX) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating $10 million in gross proceeds before deducting underwriting fees and expenses, according to a company statement.
The Tel Aviv-based clinical-stage pharmaceutical company’s shares began trading on the NYSE American exchange on August 13, 2025, under the ticker symbol NSRX. The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares at the offering price, minus underwriting discounts and commissions.
Nasus Pharma focuses on developing intranasal products for emergency medical conditions. The company plans to use net proceeds to advance its intranasal epinephrine program, including manufacturing scale-up and additional Phase 2 studies. Remaining funds will support general corporate purposes, working capital, and capital expenditures.
The company’s lead product candidate, NS002, is an intranasal powder epinephrine product designed as a needle-free alternative to epinephrine autoinjectors for patients with anaphylaxis. The product uses the company’s proprietary powder-based intranasal technology for drug delivery through the nasal cavity’s vascular network.
Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC served as joint bookrunners for the offering. The Securities and Exchange Commission declared the company’s registration statement on Form F-1 effective on August 12, 2025.